These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 38883164)

  • 1. Updates of primary central nervous system lymphoma.
    Wu J; Zhou D; Zhu X; Zhang Y; Xiao Y
    Ther Adv Hematol; 2024; 15():20406207241259010. PubMed ID: 38883164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.
    Zhai Y; Zhou X; Wang X
    Ther Adv Med Oncol; 2022; 14():17588359221093745. PubMed ID: 35558005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on Novel Therapeutics for Primary CNS Lymphoma.
    Schaff LR; Grommes C
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
    Shen J; Liu J
    Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
    Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
    Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targets and treatments in primary CNS lymphoma.
    von Roemeling C; Ferreri AJM; Soussain C; Tun HW; Grommes C
    Leuk Lymphoma; 2024 Aug; 65(8):1055-1067. PubMed ID: 38659230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatment strategies for primary lymphoma of the central nervous system].
    Seidel S; Kaulen L; von Baumgarten L
    Nervenarzt; 2024 Feb; 95(2):117-124. PubMed ID: 37910181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
    Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
    Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances and challenges in primary central nervous system lymphoma: a narrative review.
    Ma L; Gong Q
    Transl Cancer Res; 2023 May; 12(5):1335-1352. PubMed ID: 37304530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma.
    Schaff LR; Grommes C
    Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the diagnosis and the treatment of primary CNS lymphoma.
    Rachdi A; Hernandez-Tost H; Herzi D; Morales-Martinez A; Hernández-Verdin I; Houillier C; Alentorn A; Hoang-Xuan K
    Rev Neurol (Paris); 2023 Jun; 179(5):481-489. PubMed ID: 37045615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
    Zhang Y; Zhou DB
    Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy or chemotherapy: a real-world study of the first-time relapsed and refractory primary central nervous system lymphoma.
    Yang Y; Li Q; Ma J; Kang H; Lin Z; Wang Y; Ma Y; Chen B
    Front Oncol; 2023; 13():1098785. PubMed ID: 37182159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma.
    Wirsching HG; Weller M; Balabanov S; Roth P
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34203062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.